Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to ...

Awards will also recognise innovation, rising stars from the ECP community, and individuals who have made outstanding ...

With the end of the pandemic, sales of Pfizer’s COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. In 2025, Pfizer’s revenues from ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...

Paxlovid is used to treat adults and children over 12 years old with mild-to-moderate coronavirus disease who are at high risk for progression to severe disease. Developed by Pfizer, Paxlovid was ...

There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are ...

Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' ...

With volatility taking center stage since the beginning of the year, investing in the stock market isn’t as easy as it was.

Pfizer stock (NYSE: PFE) recently reported its Q1 results, with revenues missing and earnings exceeding the street estimates. The company reported revenue of $13.7 billion and adjusted earnings of ...

the prime "challenge" for Pfizer is that it's being punished for its own previous success. After its two blockbuster COVID-19 therapies, Comirnaty and Paxlovid, brought in more than $56 billion in ...